The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Enrolled patients will undergo whole-body\[18F\]F-RESCA-RT4(Trop2-targeted imaging probes ) or \[18F\]F-RESCA-RB14(HER2-targeted imaging probes) PET/CT scans at 1 hours after tracer injection(0.05-0.1 mCi/kg). Uptake of above imaging agents in tumor and normal organs/tissues will be scored visually and quantitatively. Tumor uptake will be quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy will be calculated to evaluate the diagnostic efficacy. The correlation between lesion uptake and protein expression level determined by immunohistochemistry staining will be further analyzed. The exploration endpoint will be the imaging feasibility and preliminary diagnostic value of the above tracers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
200
Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RT4 injection.
Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
RECRUITINGBiodistribution of [18F]F-RESCA-RT4/ [18F]F-RESCA-RB14
Measurement of the overall biodistribution of above probes in normal tissues and organs.
Time frame: 1 day from injection of the tracer
Standardized uptake value (SUV)
Standardized uptake value (SUV) of \[18F\]F-RESCA-RT4/ \[18F\]F-RESCA-RB14 in the included subjects' primary and/or metastatic lesions.
Time frame: 1 day from injection of the tracer
Radiation dosimetry of [18F]F-RESCA-RT4/[18F]F-RESCA-RB14
Measurement of absorbed radiation doses (Gy/MBq) to tissues/organs, tumor(s), and whole body (Sv/MBq). Dynamic imaging within one hour will be acquired for the purpose.
Time frame: 1 day from injection of the tracer
The correlation between Trop2 expression and [18F]F-RESCA-RT4 uptake value
The Standardized uptake value (SUV) of \[18F\]F-RESCA-RT4 will be calculated, and the correlation between pathological results and tumor uptake of\[18F\]F-RESCA-T4 will be analyzed.
Time frame: 60 days
The correlation between HER2 expression and [18F]F-RESCA-RB14 uptake value
Standardized uptake value (SUV) of \[18F\]F-RESCA-RB14 will be calculated, and the correlation between pathological results and tumor uptake of \[18F\]F-RESCA-RB14 will be analyzed.
Time frame: 60 days
Diagnostic value of Trop2/HER2-targeted immunPET in patients with breast cancer
We will calculate the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of \[18F\]F-RESCA-RT4/\[18F\]F-RESCA-RB14 PET/CT in patients with breast cancer. We will also compare the diagnostic value of above probes with that of traditional imaging tracers (e.g., 18F-FDG) and imaging modalities (e.g., MRI). All the above goals will be achieved by analyzing the static/dynamic\[18F\]F-RESCA-RT4/\[18F\]F-RESCA-RB14 PET/CT imaging data. Systematic evaluation of these parameters will elucidate the pharmacokinetics, pharmacodynamics, and, more importantly, the clinical value of \[18F\]F-RESCA-RT4/\[18F\]F-RESCA-RB14 PET/CT for patients with breast cancer.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 30 days
The predictive value of [18F]F-RESCA-RT4/ [18F]F-RESCA-RB14 in the course of targeted therapies
Baseline and follow-up \[18F\]F-RESCA-RT4/ \[18F\]F-RESCA-RB14 immunoPET imaging in targeted therapy will be investigated in this setting to determine the value of Trop2/HER2 immunoPET imaging in predicting or evaluating treatment responses.
Time frame: 3-6 months
Trop2/HER2-targeted immunPET in changing clinical decision-making for patients with breast cancer
After analyzing the imaging parameters and diagnostic/predictive value of \[18F\]F-RESCA-RT4/\[18F\]F-RESCA-RB14 PET/CT, we will also investigate how clinical use of \[18F\]F-RESCA-RT4/\[18F\]F-RESCA-RB14 PET/CT changes clinical decision-making for patients with breast cancer. Joint efforts from nuclear medicine physicians, breast surgeons, oncologists, and pathologists will draw solid conclusions from the imaging and clinical information.
Time frame: 3-6 months